Shreis selected by NIH AAP Program

Shreis Scalene Therapeutics submission to apply for an appropriate SBIR-Phase I grant for its CELLFORN®- targeted, drug delivery technology - was successfully accepted into the highly competitive and newly announced NIH-SBIR-Application Assistance Program (AAP), for small businesses, in January 2020. The pro-bono assistance of the Eva Garland Consulting (www.evagarland.com ) group  in developing the Research Strategy and Specific Aims for thorough review by an NIH program Director, was invaluable and will lead to a Grant proposal submission in the Fall cycle of 2020.